Shares of companies with Alzheimer's programs are trading after Biogen and Elsai announced Lecanemab treatment its the primary endpoint and reduced clinical decline on the global cognitive and functional scale.
Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.